Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims

1. (currently amended) A method of treating a Pervasive Developmental Disorder selected from the group consisting of Asperger's Disorder, Rett's Disorder, Childhood Disintegrative Disorder, and Pervasive Developmental Disorder Not Otherwise Specified, comprising administering to a patient in need of such treatment an effective amount of a norepinephrine reuptake inhibitor selected from the group consisting of:

atomoxetine or a pharmaceutically acceptable salt thereof~~;~~ and

~~racemic reboxetine or a pharmaceutically acceptable salt thereof;~~

~~(S,S) reboxetine or a pharmaceutically acceptable salt thereof;~~

a compound of formula (I):



(I)

wherein X is C_1-C_4 alkylthio, and Y is C_1-C_2 alkyl, or a pharmaceutically acceptable salt thereof~~;~~ as sole active agent.

~~a compound of formula (IA):~~



(IA)

~~wherein n is 1, 2 or 3; R1 is C_2-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_8cycloalkyl or C_4-C_{10}cycloalkylalkyl, wherein one C-C bond within any cycloalkyl moiety is optionally substituted by an O-C or C=C bond and wherein each group is optionally substituted with~~

~~from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C_1-C_4alkyl and C_1-C_4alkoxy; R2 is H, C_1-C_4alkyl (optionally substituted with from 1 to 7 halogen atoms), C_1-C_4alkyl-$S(O)_x$- wherein x is 0, 1 or 2 (optionally substituted with from 1 to 7 halogen atoms), C_1-C_4alkoxy (optionally substituted with from 1 to 7 halogen atoms), cyano, halogen, phenyl (optionally substituted with from 1 to 3 substituents each independently selected from halogen, C_1-C_4alkyl and C_1-C_4alkoxy), phenoxy (optionally substituted with from 1 to 3 substituents each independently selected from halogen, C_1-C_4alkyl and C_1-C_4alkoxy) or $-CO_2(C_1$-C_4alkyl), or together with R3 forms a further benzene ring (optionally substituted with from 1 to 3 substituents each independently selected from halogen, C_1-C_4alkyl and C_1-C_4alkoxy); R3 is H, C_1-C_4alkyl (optionally substituted with from 1 to 7 halogen atoms), C_1-C_4alkyl-$S(O)_x$- wherein x is 0, 1 or 2 (optionally substituted with from 1 to 7 halogen atoms), C_1-C_4alkoxy (optionally substituted with from 1 to 7 halogen atoms), cyano, halogen, phenyl (optionally substituted with from 1 to 3 substituents each independently selected from halogen, C_1-C_4alkyl and C_1-C_4alkoxy), phenoxy (optionally substituted with from 1 to 3 substituents each independently selected from halogen, C_1-C_4alkyl and C_1-C_4alkoxy) or $-CO_2(C_1$-C_4alkyl), or together with R2 or R4 forms a further benzene ring (optionally substituted with from 1 to 3 substituents each independently selected from halogen, C_1-C_4alkyl and C_1-C_4alkoxy); R4 is H, C_1-C_4alkyl (optionally substituted with from 1 to 7 halogen atoms), C_1-C_4alkyl-$S(O)_x$- wherein x is 0, 1 or 2 (optionally substituted with from 1 to 7 halogen atoms), C_1-C_4alkoxy (optionally substituted with from 1 to 7 halogen atoms), cyano, halogen, phenyl (optionally substituted with from 1 to 3 substituents each independently selected from halogen, C_1-C_4alkyl and C_1-C_4alkoxy), phenoxy (optionally substituted with from 1 to 3 substituents each independently selected from halogen, C_1-C_4alkyl and C_1-C_4alkoxy) or $-CO_2(C_1$-C_4alkyl), or together with R3 forms a further benzene ring (optionally substituted with from 1 to 3 substituents each independently selected from halogen, C_1-C_4alkyl and C_1-C_4alkoxy); R5 is H, C_1-C_4alkyl (optionally substituted with from 1 to 7 halogen atoms), C_1-C_4alkoxy (optionally substituted with from 1 to 7 halogen atoms) or halogen; R6 is H, C_1-C_4alkyl (optionally substituted with from 1 to 7 halogen atoms), C_1-C_4alkoxy (optionally substituted with from 1 to 7 halogen atoms) or halogen; R7 is H or C_1-C_4alkyl; R8 is H or C_1-C_4alkyl; R9 is H, halogen, hydroxy, cyano, C_1-C_4alkyl or C_1-C_4alkoxy; and R10 is H, halogen, hydroxy, cyano, C_1-C_4alkyl or C_1-C_4alkoxy; or a pharmaceutically acceptable salt thereof; with the proviso that the compound N-ethyl-N-benzyl-4-piperidinamine is excluded;~~

~~a compound of formula (IB):~~



~~(IB)~~

~~wherein Rx is H; Ry is H or C_1-C_4 alkyl; each Rz is independently H or C_1-C_4 alkyl; X represents O; Y represents OH or OR; R is C_1-C_4 alkyl; Ar_1 is a phenyl ring or a 5- or 6-membered heteroaryl ring each of which may be substituted with 1, 2, 3, 4 or 5 substituents (depending upon the number of available substitution positions) each independently selected from C_1-C_4 alkyl, O(C_1-C_4 alkyl), S(C_1-C_4 alkyl), halo, hydroxy, pyridyl, thiophenyl and phenyl optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from halo, C_1-C_4 alkyl, or O(C_1-C_4 alkyl); and Ar_2 is a phenyl ring or a 5- or 6-membered heteroaryl ring each of which may be substituted with 1, 2, 3, 4 or 5 substituents (depending upon the number of available substitution positions) each independently selected from C_1-C_4 alkyl, O(C_1-C_4 alkyl) and halo; wherein each above-mentioned C_1-C_4 alkyl group is optionally substituted with one or more halo atoms; or a pharmaceutically acceptable salt thereof;~~

~~a compound of formula (IC)~~



~~(IC)~~

~~wherein: A is S or O; R is H; Ar is a phenyl group optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from C_1-C_4 alkyl, O(C_1-C_4 alkyl), S(C_1-C_4 alkyl), halo, hydroxy, CO_2(C_1-C_4 alkyl), pyridyl, thiophenyl and phenyl optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from halo, C_1-C_4 alkyl, or O(C_1-C_4 alkyl); X is a phenyl group optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from halo, C_1-C_4 alkyl, or O(C_1-C_4 alkyl); a C_1-C_4~~

~~alkyl group; a C_3-C_6-cycloalkyl group or a CH_2(C_3-C_6-cycloalkyl) group; R' is H or C_1-C_4 alkyl; each R^1 is independently H or C_1-C_4-alkyl; wherein each above-mentioned C_1-C_4 alkyl group is optionally substituted with one or more halo atoms; or a pharmaceutically acceptable salt thereof; with the proviso that, when A is O, X is a C_1-C_4-alkyl group, a C_3-C_6 cycloalkyl group or a CH_2(C_3-C_6-cycloalkyl) group;~~

~~a compound of formula (ID)~~



~~(ID)~~

~~wherein X is C(R^4R^5), O or S; n is 2 or 3; R^1 is H or C_1-C_4-alkyl; R^3 is H, halo, C_1-C_4 alkyl, O(C_1-C_4-alkyl), nitrile, phenyl or substituted phenyl; R^4 and R^5 are each independently selected from H or C_1-C_4-alkyl; Ar is selected from the group consisting of~~



~~in which R^{2a} is H, halo, methyl or ethyl; R^{2b} is H, halo or methyl; R^{2c} is H, halo, methyl, trifluoromethyl, nitrile, or methoxy; R^{2d} is H, halo, methyl or ethyl; R^{2e} is H, halo, methyl, trifluoromethyl, nitrile, or methoxy; R^{2f} is H, or fluoro; Y is O, S or N(R^6); and R^6 is H or methyl or a pharmaceutically acceptable salt thereof;~~

~~a compound of formula (IE)~~



~~(IE)~~

~~wherein R^1 is C_1-C_6 alkyl (optionally substituted with 1, 2 or 3 halo substituents and/or with 1 substituent selected from S-(C_1-C_3-alkyl), O-(C_1-C_3-alkyl) (optionally substituted with 1, 2~~

or 3 F atoms), -O-(C_3-C_6-cycloalkyl), -SO_2-(C_1-C_3-alkyl), -CN, -COO-(C_1-C_2-alkyl) and -OH); C_2-C_6-alkenyl; -$(CH_2)_q$-Ar_2; or a group of formula (i) or (ii)



(i) (ii)

R^2, R^3 and R^4 are each independently selected from hydrogen or C_1-C_2-alkyl; R^5, R^6, R^7 and R^8 are at each occurrence independently selected from hydrogen or C_1-C_2-alkyl; -X- is a bond, -CH_2-, -CH=CH-, -O-, -S-, or -SO_2-; -Y- is a bond, -CH_2- or -O-; -Z is hydrogen, -OH or -O-(C_1-C_3-alkyl); p is 0, 1 or 2; q is 0, 1 or 2; r is 0 or 1; s is 0, 1, 2 or 3; t is 0, 1, 2 or 3; Ar_1 is phenyl, pyridyl, thiazolyl, benzothiophenyl or naphthyl; wherein said phenyl, pyridyl or thiazolyl group may be substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, C_1-C_4-alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C_1-C_4-alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C_1-C_4-alkyl) (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridyl, pyrazole, phenyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents); and wherein said benzothiophenyl or naphthyl group may be optionally substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, C_1-C_4-alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C_1-C_4-alkyl) (optionally substituted with 1, 2 or 3 F atoms), and -S-(C_1-C_4-alkyl) (optionally substituted with 1, 2 or 3 F atoms); Ar_2 is naphthyl, pyridyl, thiazolyl, furyl, thiophenyl, benzothiophenyl, or phenyl, wherein said naphthyl, pyridyl, thiazolyl, furyl, thiophenyl, benzothiophenyl, or phenyl may be substituted with 1, 2 or 3 substituents each independently selected from halo, C_1-C_4-alkyl (optionally substituted with 1, 2 or 3 F atoms) and -O-(C_1-C_4-alkyl) (optionally substituted with 1, 2 or 3 F atoms); or a pharmaceutically acceptable salt thereof; provided that (a) the cyclic portion of the group of formula (i) must contain at least three carbon atoms and not more than seven ring atoms; (b) when -X- is -CH=CH-, then the cyclic portion of the group of formula (i) must contain at least five carbon atoms; and (c) when -Z is -OH or -O-(C_1-C_3-alkyl), then -X- is -CH_2-; (d) when -Y- is -O- then p cannot be 0; and (e) the compound 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile is excluded;

a compound of formula (IF)



~~(IF)~~

~~wherein~~



is a group of formula (a) or (b)



~~(a)~~ ~~(b)~~

~~R^1 is C_1-C_6 alkyl (optionally substituted with 1, 2 or 3 halo substituents and/or with 1 substituent selected from -S-(C_1-C_3 alkyl), -O-(C_1-C_3 alkyl) (optionally substituted with 1, 2 or 3 F atoms), -O-(C_3-C_6 cycloalkyl), SO_2-(C_1-C_3 alkyl), -CN, -COO-(C_1-C_2 alkyl) and -OH); C_2-C_6 alkenyl; $(CH_2)_q$-Ar_2; or a group of formula (i) or (ii)~~



~~(i)~~ ~~(ii)~~

~~R^2, R^3 and R^4 are each independently selected from hydrogen or C_1-C_2 alkyl; R^5, R^6, R^7 and R^8 are at each occurrence independently selected from hydrogen or C_1-C_2 alkyl; X is a bond, $-CH_2-$, -CH=CH-, -O-, -S-, or $-SO_2-$; Y is a bond, $-CH_2-$ or -O-; Z is hydrogen, -OH or -O-(C_1-C_3 alkyl); p is 0, 1 or 2; q is 0, 1 or 2; r is 0 or 1; s is 0, 1, 2 or 3; t is 0, 1, 2 or 3; Ar_1 is phenyl, pyridyl, thiazolyl, benzothiophenyl or naphthyl; wherein said phenyl, pyridyl or thiazolyl group may be substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C_1-C_4 alkyl) (optionally substituted~~

~~with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridyl, pyrazole, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl and phenoxy (optionally substituted with 1, 2 or 3 halo substituents); and wherein said benzothiophenyl or naphthyl group may be optionally substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms), and -S-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms); Ar_2 is naphthyl, pyridyl, thiazolyl, furyl, thiophenyl, benzothiophenyl, or phenyl, wherein said naphthyl, pyridyl, thiazolyl, furyl, thiophenyl, benzothiophenyl, or phenyl may be substituted with 1, 2 or 3 substituents each independently selected from halo, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms) and -O-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms); or a pharmaceutically acceptable salt thereof; provided that (a) the cyclic portion of the group of formula (i) must contain at least three carbon atoms and not more than seven ring atoms; (b) when -X- is -CH=CH-, then the cyclic portion of the group of formula (i) must contain at least five carbon atoms; and (c) when -Z is -OH or -O-(C_1-C_3 alkyl), then -X- is $-CH_2-$; and (d) when -Y- is -O- then p cannot be 0; and~~

~~a compound of formula (IG)~~



~~(IG)~~

~~wherein -X- is -S- or -O-; each R is independently selected from H or C_1-C_4 alkyl; R^1 is H, C_1-C_4 alkyl, C_1-C_4 alkoxy, halo, cyano, trifluoromethyl, trifluoromethoxy, $-NR^3R^4$, $-CONR^3R^4$, $-COOR^3$ or a group of the formula (i)~~



(i)

~~R^2 is C_1-C_4 alkyl, phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, nitro, hydroxy, cyano, halo, trifluoromethyl,~~

~~trifluoromethoxy, benzyl, benzyloxy, NR^6R^7, $CONR^6R^7$, $COOR^6$, $SO_2NR^6R^7$ and SO_2R^6; R^5 is selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, carboxy, nitro, hydroxy, cyano, halo, trifluoromethyl, trifluoromethoxy, benzyl, benzyloxy, NR^8R^9, $CONR^8R^9$, $SO_2NR^8R^9$ and SO_2R^8; R^3, R^4, R^6, R^7, R^8 and R^9 are each independently selected from H or C_1-C_4 alkyl; and Z is a bond, CH_2, or O;~~

~~or a pharmaceutically acceptable salt thereof.~~

2. (cancelled)

3. (cancelled)

4. (currently amended) The method of claim 1 ~~or 3, or the use of claim 2 or 3~~, wherein said selective norepinehprine reuptake inhibitor is atomoxetine hydrochloride.

5. (newly added) The method of claim 1, wherein attention-deficit/hyperactivity disorder occurs comorbidly with said Pervasive Developmental Disorder.

6. (newly added) The method of claim 4, wherein attention-deficit/hyperactivity disorder occurs comorbidly with said Pervasive Developmental Disorder.